HER2/ErbB2 (29D8) Rabbit mAbProduct information
|100 µl (10 western blots)||-||Unavailable in your region|
Product Pathways - Tyrosine Kinase / Adaptors
HER2/ErbB2 (29D8) Rabbit mAb #2165
|2165S||100 µl (10 western blots)||---||In Stock||---|
|2165||carrier free and custom formulation / quantity||email request|
|W||1:1000||Human, Mouse||Endogenous||185||Rabbit IgG|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation, IHC-P=Immunohistochemistry (Paraffin), IHC-F=Immunohistochemistry (Frozen), IF-IC=Immunofluorescence (Immunocytochemistry), F=Flow Cytometry
Species predicted to react based on 100% sequence homology: Rat.
Specificity / Sensitivity
HER2/ErbB2 (29D8) Rabbit mAb detects endogenous levels of total ErbB2 protein. This antibody does not cross-react with related kinases.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding tyrosine 1248 of human ErbB2 protein.
Western blot analysis of cell extracts from various cell lines, using HER2/ErbB2 (29D8) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using HER2/ErbB2 (29D8) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using HER2/ErbB2 (29D8) RmAb in the presence of control peptide (left) or HER2/ErbB2 Blocking Peptide #1059 (right).
Immunohistochemical analysis of paraffin-embedded SKBr3 (high HER2) (left), MDA-MB-453 (moderate HER2) (middle) and MDA-MB-468 (low HER2) (right), using HER2/ErbB2 (29D8) Rabbit mAb.
Immunohistochemical analysis of frozen SKOV-3 xenograft using HER2/ErbB2 (29D8) Rabbit mAb.
Confocal immunofluorescent analysis of MDA-MB-453 cells (left) and MDA-MB-231 cells (right), using HER2/ErbB2 (29D8) Rabbit mAb (green). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye).
The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7727 Biotinylated Protein Ladder Detection Pack
- 2248 HER2/ErbB2 (44E7) Mouse mAb
- 4290 HER2/ErbB2 (D8F12) XP® Rabbit mAb
- 3250 HER2/ErbB2 (M45) Antibody
- 2242 HER2/ErbB2 Antibody
- 1059 HER2/ErbB2 Blocking Peptide
- 6942 Phospho-HER2/ErbB2 (Tyr1196) (D66B7) Rabbit mAb
- 2243 Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb
- 2249 Phospho-HER2/ErbB2 (Tyr1221/1222) Antibody
- 2247 Phospho-HER2/ErbB2 (Tyr1248) Antibody
- 2244 Phospho-HER2/ErbB2 (Tyr1248)/EGFR (Tyr1173) Antibody
- 2241 Phospho-HER2/ErbB2 (Tyr877) Antibody
- 9923 Phospho-HER2/ErbB2 Antibody Sampler Kit
- 6883 SignalFire™ ECL Reagent
- 12757 SignalFire™ Elite ECL Reagent
- 12630 SignalFire™ Plus ECL Reagent
- 8117 SignalSlide® Phospho-ErbB Family IHC Controls
- 8112 SignalStain® Antibody Diluent
- 8059 SignalStain® DAB Substrate Kit
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
DRAQ5 is a registered trademark of Biostatus Limited.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.